Company: NOTV
Filing Date: 2025-08-29
Form Type: S-3
Source: 0001628280-25-041413
Chunk: 54

Company: Inotiv, Inc.
Filing Date: 2025-08-29
Form: S-3
Chunk 54
---
 which can reduce nonclinical lead times and provide enhanced project delivery. In conjunction with our DSA business, we have the ability to run selected nonclinical studies directly on-site at closely located research model facilities and provide access to innovative genetically engineered models and services solutions. Our principal clients include biopharmaceutical companies, CROs, and academic and government organizations.

#### Our Corporate Information
We were incorporated in the state of Indiana in July 1975. Our principal executive offices are located at 2701 Kent Avenue, West Lafayette, Indiana 47906, and our telephone number is (765) 463-4527. Our Internet website is www.inotivco.com. The information contained on our website is not a part of this prospectus and is not incorporated by reference herein.

<div align='center'>S-4</div>

THE OFFERING

| Issuer                      |     | Inotiv, Inc.                                                                                                                                                                                                                                                                        |
| Common shares offered by us |     | Common shares having an aggregate offering price of up to $50.0 million.                                                                                                                                                                                                            |
| Manner of offering          |     | “At the market offering” that may be made from time to time through Jefferies. See “Plan of Distribution” below.                                                                                                                                                                    |
| Use of proceeds             |     | We currently intend to use any net proceeds from this offering primarily for working capital and other general corporate purposes. See “Use of Proceeds” below.                                                                                                                     |
| Risk factors                |     | See “Risk Factors” beginning on pageS-6of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors that you should read and consider before investing in our securities. |
| Nasdaq ticker symbol        |     | “NOTV”                                                                                                                                                                                                                                                                              |

<div align='center'>S-5</div>

### RISK FACTORS
An investment in our common shares involves risks. You should consider carefully the following risks and all of the other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, including “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K and “Part II, Item 1A. Risk Factors” in our Quarterly Reports on Form 10-Q, which are incorporated by reference herein, before investing in our common shares. If any of these risks actually occur, our business, prospects, operating results and financial condition could suffer materially